姓名：贾继东 性别：男 职称：主任医师、教授 招生院所：附属友谊医院 招生类型：科学与专业学位(博) 科学与专业学位(硕) 招生专业：内科学（消化系病）(博) 内科学（消化系病）(硕) 研究方向名称：肝纤维化的发病机制及诊断治疗 电子信箱：yangaiting168@126.com


社会任职
1. 中国医师协会消化医师分会专业委员会肝病学分会 主任委员（2018.07-至今）
2. 中国肝炎防治基金会 副理事长（2008.01-至今）
3. 中华医学会肝病学分会 主任委员（2006.11-2012.11）
4. 亚太肝病学会 主席（2009.03-2010.03）
5. 国际肝病学会主席（2015.01-2016.01）
6.
7.
8.
个人简历
1. 197809-198107:山东省济宁医学专科学校医学系 大专
2. 198107-198709:山东省单县中心医院 住院医师
3. 198709-199009:兰州医学院 硕士研究生
4. 199009-199307:首都医科大学 博士研究生
5. 199307-:首都医科大学附属北京友谊医院肝病中心 主任
6. 199702-199902:德国柏林自由大学医学院 博士后
重要学术论文
1. Sun Y, Wu X, Zhou J, Meng T, Wang B, Chen S, Liu H, Wang T, Zhao X, Wu S, Kong Y, Ou X, Wee A, Theise ND, Qiu C, Zhang W, Lu F, Jia J*, You H*.Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. Clinical Gastroenterology and Hepatology. 2020,【未填写卷（期）】:【未填写起止页码】.SCI
2. Zhang C, Jin H, Wang Y, Li C, Zhao X, Li Y, Shi W, Tian Y, Xu H, Tian D, Liu K, Jia J*, Sun G*, Zhang D*..Critical role of OX40 in drug-induced acute liver injury. British Journal of Pharmacology. 2020,【未填写卷（期）】:【未填写起止页码】.SCI
3. Li M, Lv T, Wu S, Wei W, Wu X, Ou X, Ma H, Chow SC, Kong Y*, You H*, Jia J*. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatology International. 2020,14(1):105-114.
4. Wang Q, You H, Ou X, Zhao X, Sun Y, Wang M, Wang P, Wang Y, Duan W, Wang X, Wu S, Kong Y, Saxena R*, Gouw ASH*, Jia J*.Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. Hepatology International. 2019,13(6):766-776.SCI
5. Zhang W, Xu A, Li Y, Zhao S, Zhou D, Wu L, Zhang B, Zhao X, Wang Y, Wang X, Duan W, Wang Q, Nan Y, You H, Jia J*, Ou X*, Huang J*.A novel SLC40A1 p.Y333H mutation with gain of function of ferroportin: A recurrent cause of haemochromatosis in China. Liver International. 2019,39(6):1120-1127.SCI
6. Jia J, Zhang M, Zang X, Zhang H, Zhao J.Dynamic Parameter Identification for a Manipulator with Joint Torque Sensors Based on an Improved Experimental Design. Sensors. 2019,19(10):【未填写起止页码】.SCI
7. Zeng N, Duan W, Chen S, Wu S, Ma H, Ou X, You H, Kong Y*, Jia J*.Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. Hepatology International. 2019,13(6):788-799.SCI
8. Wang T*, Zhao X, Shao C, Ye L, Guo J, Peng N, Zhang H, Li J, Kong Y, You H*, Jia J*.A proposed pathologic sub-classification of drug-induced liver injury. Hepatology International. 2019,13(3):339-351.SCI
9. Fan W, Liu T, Chen W, Hammad S, Longerich T, Hausser I, Fu Y, Li N, He Y, Liu C, Zhang Y, Lian Q, Zhao X, Yan C, Li L, Yi C, Ling Z, Ma L, Zhao X, Xu H, Wang P, Cong M, You H, Liu Z, Wang Y, Chen J, Li D, Hui L, Dooley S*, Hou J*, Jia J*, Sun B*.ECM1 Prevents Activation of Transforming Growth Factor beta, Hepatic Stellate Cells, and Fibrogenesis in Mice. Gastroenterology. 2019,157(5):1352-1367.SCI
10. Chen S, Duan W, Li M, Li S, Lv T, Tian Q, Wang Q, Wu X, Zhao X, Wang X, Wang Y, Kong Y, Ma H, Ou X, You H, Jia J*.Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China. Journal of Gastroenterology and Hepatology. 2019,34(7):1236-1241.SCI
11. Wang Y, Wang L, Saxena R, Wee A, Yang R, Tian Q, Zhang J, Zhao X*, Jia J*.Clinicopathological features of He Shou Wu-induced liver injury: This ancient anti-aging therapy is not liver-friendly. Liver International. 2019,39(2):389-400.SCI
12. Kong Y, Sun Y, Zhou J, Wu X, Chen Y, Piao H, Lu L, Ding H, Nan Y, Jiang W, Xu Y, Xie W, Li H, Feng B, Shi G, Chen G, Li H, Zheng H, Cheng J, Wang T, Liu H, Lv F, Shao C, Mao Y, Sun J, Chen T, Han T, Han Y, Wang L, Ou X, Zhang H, Jia J*, You H*.Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. Journal of Viral Hepatitis. 2019,26(5):1499-1509.SCI
13. Wang L, Wang B, You H, Wu X, Zhou J, Ou X, Jia J*.Platelets' increase is associated with improvement of liver fibrosis in entecavir-treated chronichepatitis Bpatients with significant liver fibrosis. Hepatology International. 2018,12(3):237-243.SCI
14. He T, Bai Y , Cai H, Ou X, Liu M, Yi W , Jia J*.Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B. Hepatology International. 2018,12(2):118-125.SCI
15. Zeng N, Zou C, He Z, Ma H, Ou X, You H, Kong Y*, Jia J*.Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China. International Journal of Infectious Diseases. 2018,67:58-64.SCI
16. Wang L,Liu T,Zhou J,You H,Jia J*.Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy. Hepatology Research. 2018,48(3):E283-E290.SCI
17. He T, Bai Y, Cai H, Ou X, Liu M, Yi W*, Jia J*.Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B. Hepatology International. 2018,12(2):118-125.SCI
18. Lv T, Zhang W, Xu A, Li Y, Zhou D, Zhang B, Li X, Zhao X, Wang Y, Wang X, Duan W, Wang Q, Xu H, Zheng J, Zhao R, Zhu L, Dong Y, Lu L, Chen Y, Long J, Zheng S, Wang W, You H, Jia J*, Ou X*, Huang J.Non-HFE mutations in haemochromatosis in China: combination of heterozygous mutations involving HJV signal peptide variants. Journal of Medical Genetics. 2018,55(10):650-660.SCI
19. Wu S, Kong Y, Piao H, Jiang W, Xie W, Chen Y, Lu L, Ma A, Xie S, Ding H, Shang J, Zhang X, Feng B, Han T, Xu X, Huo L, Cheng J, Li H, Wu X, Zhou J, Sun Y, Ou X, Zhang H, You H, Jia J*.On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis. Liver International. 2018,38(6):1045-1054.SCI
20. Shan S, Cui F, Jia J*.How to control highly endemic hepatitis B in Asia. Liver International. 2018,38(Suppl 1):122-125.SCI
21. Duan W, Ou X, Wang X, Wang Y, Zhao X, Wang Q, Wu X, Zhang W, Ma H, You H, Jia J*.Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. Revista Espanola de Enfermedades Digestivas. 2018,110(9):557-563.SCI
22. Chen S, Duan W, You H, Jia J*..A brief review on prognostic models of primary biliary cholangitis. Hepatology International. 2017,11(5):412-418.SCI
23. Cong M, Zhao W, Liu T, Wang P, Fan X, Zhai Q, Bao X, Zhang D, You H, Kisseleva T, Brenner DA, Jia J*, Zhuang H*.Protective effect of human serum amyloid P on CCl4-induced acute liver injury in mice. International Journal of Molecular Medicine. 2017,40(2):454-464.SCI
24. Sun Y, Zhou J, Wang L, Wu X, Chen Y, Piao H, Lu L, Jiang W, Xu Y, Feng B, Nan Y, Xie W, Chen G, Zheng H, Li H, Ding H, Liu H, Lv F, Chen Shao, Wang T, Ou X, Wang B, Chen S, Wee A, Theise ND*, You H*, Jia J*..New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients Before and After Treatment. Hepatology. 2017,65(5):1438-1450.SCI
25. Tang W, Wang Y, Zhao X, Wang X, Zhang T, Ou X, Shou W, You H, Jia J*..Procoagulant imbalance aggravated with falling liver function reserve, but not associated with the presence of portal vein thrombosis in cirrhosis. European Journal of Gastroenterology & Hepatology . 2015,27(6):672-8.SCI
26. Niu Y, Chen X, Feng L, You H, Ren X, Liu H, Zheng J, Shen Z, Jia J*..Anti-HBc-positive/HBsAg-negative liverdonors pose a higher risk of occult HBVinfection but do not cause severehistological damage in liver grafts.. . Clin Res Hepatol Gastroenterol. 2014,38(4):475-80.SCI
27. Yu Z, Wang Y, Feng L, Jia J*.Macro-aspartate aminotransferase_ two-year follow-up of three patients in China. Dig Dis Sci. 2014,59(1):224-6.SCI
28. Wang Y, Hong Y, Li M, Long J, Zhao YP, Zhang JX, Li Q, You H, Tong WM, Jia JD, Huang J.. Mutation Inactivation of Nijmegen Breakage Syndrome Gene (NBS1) in Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.. PLoS One. . 2013,8(12):e82426.SCI
29. Feng L, Niu Y, Chen H, You H, Zang Y, Li L, Shan S, Tan Y, Jia J*, Shen Z.Immunogenicity of different hepatitis B virus vaccination schedules in liver transplant recipients. Hepatology Research. 2013,43(5):495-501.SCI
30. Bai Q, An J, Wu X, You H, Ma H, Liu T, Gao N, Jia J*.HBV promotes the proliferation of hepatic stellate cells via the PDGF-B/PDGFR-β signaling pathway in vitro. Int J Mol Med. 2012,30(6):1443-50.SCI
31. Wu X, Wang Y, Cui Y, Bai Q, Ze X, Liu T, Cong M, Wang P, Li X, Yin G, Ou X, You H, Jia J*.Hepatitis B virus directly promotes collagen I expression of LX-2 cells without infection in vitro. Hepatol Res. 2012,42(9):911-21.SCI
32. Li H, Zheng HW, Chen H, Xing ZZ, You H, Cong M, Jia JD*.Hepatitis B virus particles preferably induce Kupffer cells to produce TGF-β1 over pro-inflammatory cytokines. Dig Liver Dis. 2012,44(4):328-33.SCI
33. Jia JD.Lactulose in the treatment of hepatic encephalopathy:New evidence for an old modality. Journal of Gastroenterology and Hepatology. 2012,27:1259–1265.SCI
34. Xing ZZ, Zhang DL, Li H, Chen H, Jia JD, Wang ZG*.Rat renal interstitial fibroblasts affect the TH1/TH2 profile in vitro. Ren Fail. 2011,33(10):1025-31.SCI
35. Li H, Zheng HW, Chen H, Xing ZZ, You H, Cong M, Jia JD*.Hepatitis B virus particles preferably induce Kupffer cells to produce TGF-β1 over pro-inflammatory cytokines. Dig Liver Dis. 2011,44(4):328-33.SCI
36. Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, Tan DM, Chen XY, Gane E, Piratvisuth T, Chen L, Xie Q, Sung JJ, Wat C, Bernaards C, Cui Y, Marcellin P*.Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.. Hepatology.. 2011,54(5):1591-9.SCI
37. Wang Y, Jia J*.Control of hepatitis B in China: prevention and treatment. Expert Rev Anti Infect Ther . 2011,9(1):21-5.SCI
38. Wang H, Zhang Y, Wang T, You H, Jia J*.N-methyl-4-isoleucine cyclosporine attenuates CCl(4) -induced liver fibrosis in rats by interacting with cyclophilin B and D. J Gastroenterol Hepatol. 2011,26:558-67.SCI
39. Zhang FK, Liu DG, Jia JD*.Antiviral therapy for hepatitis B in special populations. Antivir Ther. 2010,15(8):1067-75.SCI
40. Jia JD, Hong M, Wei L, Zhang XX, Mao YL, Wang LL, Gao ZL, Hou JL, Zhang J*.Multicentre evaluation of the Elecsys hepatitis B surface antigen II assay for detection of HBsAg in comparison with other commercially available assays. .Med Microbiol Immunol . 2009,198(4):263-9.SCI
41. Liu X, Zhu ST, You H, Cong M, Liu TH, Wang BE, Jia JD*.Hepatitis B virus infects hepatic stellate cells and affects their proliferation and expression of collagen type I. Chin Med J (Engl) . 2009,122(12):1455-61.SCI
42. Jia JD.Antiviral therapy for various stages of HBV-related diseases: lamivudine and beyond.. Journal of Gastroenterology and Hepatology. 2008,23(5)::681-2..SCI
43. Jia JD, Zhuang H..A winning war against hepatitis B virus infection in China.. Chin Med J (Engl).. 2007,120(24):2157-8..SCI
44. 贾继东.抗乙型肝炎病毒治疗的疗程要多长? . 中华肝脏病杂志. 2006,（11）:835.无
45. Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken EO, Schuppan D*..Herbal products and evidence-based medicine.. CJIM. 2005,:11(1):3-4.SCI
46. Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken EO, Schuppan D*..Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliar fibrosis.. Gut. 2002,:50(2):241-7..SCI
47. Sedlaczek N, Jia JD, Bauer M, Herbst H, Ruehl M, Hahn EG, Schuppan D*..Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis.. Am J Pathol. 2001,:158(4):1239-44.SCI
48. Jia JD, Bauer M, Sedlaczek N, Herbst H, Ruehl M, Hahn EG, Riecken EO, Schuppan D*..Modulation of collagen XVIII/endostatin in lobular and biliary rat liver fibrogenesis. J Hepatol. 2001,;35:386-91.SCI
主编或副主编的著作/译著
1. 《物理诊断学》,主编,北京大学医学出版社,201901
2. 《Clinical Diagnostics》,主编,高等教育出版社,201704
3. 《乙型肝炎和丙型肝炎实验诊断与致癌机制》,主编,人民卫生出版社,201104
4. 《消化内科高级教程 》,副主编,人民军医出版社,200911
5. 《Chronic Inflammation of Liver and Gut》,主编,Springer出版社,200904
6. 《脂肪肝性肝病诊疗进展》,主编,人民卫生出版社,2009
7. 《现代肝脏病学》,副主编,科学出版社,200308
重要奖项
1. 乙肝相关性肝病肝移植受体抗乙肝措施应用性研究和临床结局改善 华夏医学科技奖 二等 201611
2. 肝纤维化防治新靶点与非创伤新诊断及干预措施的应用 中华科技奖 三等 201112
3. 肝纤维化显型表达与非创伤性诊断和临床干预 国家科技进步奖 二等 201112
4. 肝移植的临床研究及应用 国家科技进步奖 二等 201011
5. 中华医学奖《肝星状细胞在肝纤维化中的作用》 三等 200803
6. 肝星状细胞在肝纤维化发生中的作用及在抗纤维化治疗中的意义 中华科技奖 三等 2007
7. 复方861对干性状细胞增殖、胶原合成及降解干预作用的体外研究 北京市科技进步奖 三等 2000
8. 阻断及逆转肝纤维化、早期肝硬化的基础及临床研究 国家科技进步奖 三等 1999
9. 阻断及逆转肝纤维化的实验及临床研究 北京市科技进步奖 二等 1998
10. 阻断及逆转肝纤维化的实验及临床研究 卫生部科技进步奖 二等 1998